iSERA Lifesciences Ltd

iSERA Lifesciences Annual Report

iSERA Lifesciences Limited has submitted its Annual Report for the financial year 2025-26. The 34th Annual General Meeting is scheduled for September 29, 2026.

iSERA Lifesciences Annual General Meeting

iSERA Lifesciences has scheduled its 34th Annual General Meeting for September 29, 2026, and appointed a scrutinizer to oversee the voting process for the event.

iSERA Lifesciences Other Announcement

iSERA Lifesciences filed its Monitoring Agency Report for the Rights Issue proceeds utilization for the quarter ended June 30, 2026.

Value

₹8.08 Cr

iSERA Lifesciences Q1 FY27 Results: Net Loss of ₹0.3 Cr

iSERA Lifesciences Ltd reported a net loss of ₹0.3 Cr for Q1 FY27.

Key figure

Net loss ₹0.3 Cr

iSERA Lifesciences Board Meeting Date

iSERA Lifesciences Ltd scheduled a board meeting for August 7, 2026. The board will consider the unaudited financial results for the quarter ended June 30, 2026.

iSERA Lifesciences Other Announcement

iSERA Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as per SEBI regulations.

iSERA Lifesciences Annual General Meeting

iSERA Lifesciences issued a corrigendum to its Postal Ballot notice. It clarifies preferential equity share allotments and post-issue capital percentages.

Covidh Technologies Board Meeting Outcome

iSERA Lifesciences approved a name change from Covidh Technologies and adopted a new logo. The Board also addressed BSE advisory matters regarding regulatory non-compliance.

Covidh Technologies Annual General Meeting

iSERA Lifesciences Limited released its postal ballot scrutinizer report. Shareholders approved resolutions including share capital increases and related party transactions with requisite majority support.

Covidh Technologies Other Announcement

iSERA Lifesciences is exempt from SEBI related party disclosure requirements for March 2026. Its capital and net worth remain below mandatory reporting thresholds.

Covidh Technologies Q4 FY26 Results: Net Profit ₹0.5 Cr, Up 150.0% YoY

Covidh Technologies Ltd reported revenue from operations of ₹1.2 Cr and net profit of ₹0.5 Cr (+150.0% YoY) for Q4 FY26.

Key figure

Net profit ₹0.5 Cr · +150.0% YoY

Covidh Technologies Financial Results

iSERA Lifesciences reported an audited annual net profit of ₹0.26 Crore for FY2026. The board also approved standalone results and noted a successful ₹8.08 Crore rights issue.

Value

₹0.26 Cr

Covidh Technologies Annual General Meeting

iSERA Lifesciences Limited issued a postal ballot notice seeking approval for several matters, including a ₹78 Crore acquisition of iSERA Biological Limited via share swap. Other items include increasing authorised share capital to ₹25 Crore and adopting new articles and memorandum of association. Remote e-voting runs from April 22 to May 21, 2026.

Value

₹78.00 Cr

Covidh Technologies Acquisition Worth ₹78 Cr

iSERA Lifesciences Limited approved the acquisition of a 100% stake in iSERA Biological Limited for ₹78 Crore via a 1:1 share swap. The transaction will be executed through a preferential allotment of 1,61,82,800 equity shares at ₹48.20 per share. Upon completion, iSERA Biological will become a wholly-owned subsidiary.

Value

₹78.00 Cr

Execution

Within 15 days of shareholder or BSE approval

Covidh Technologies Board Meeting Outcome

iSERA Lifesciences Limited approved the acquisition of 100% stake in iSERA Biological Limited for ₹78 Crore via a share swap. The board also approved increasing authorised share capital to ₹25 Crore and adopting a new Memorandum and Articles of Association. The acquisition will make iSERA Biological a wholly-owned subsidiary, creating strategic synergies in the pharmaceutical sector.

Value

₹78.00 Cr

Covidh Technologies Board Meeting Date

iSERA Lifesciences Limited has deferred its Board Meeting scheduled for April 20, 2026. The meeting was intended to consider a preferential issue of equity shares on a private placement basis. The deferment is due to additional time required for procedural and documentation formalities related to the proposed issuance.

Covidh Technologies Board Meeting Outcome

iSERA Lifesciences Limited has scheduled a Board Meeting on April 20, 2026. The board will consider and approve a preferential issue of equity shares on a private placement basis. This move indicates the company's intent to raise capital for strategic purposes.

Covidh Technologies Capital Structure Change

Covidh Technologies Limited has officially changed its name to iSERA Lifesciences Limited effective April 10, 2026. The Registrar of Companies, Pune, approved the change and the consequent alteration of the company's Memorandum and Articles of Association. This rebranding follows a special resolution passed by members at an EGM on April 2, 2026.